Evidence map›Paper›PMID 31573951›Full record

ArticleJMIR research protocols2019

Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy.

Gabriele Calaminus, Meriel Jenney, Lars Hjorth, Katja Baust, Mark Bernstein, Stefan Bielack, Patricia De Vos, Pancras C W Hogendoorn, Gordana Jovic, Mark Krailo and 11 more

Open access · goldAbstract read
In one paragraph

Article in JMIR research protocols, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 13 institutions in 8 countries.

Gabriele CalaminusDepartment of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0002-7893-7982
Meriel JenneyChildren & Women's Services Clinical Board, University Hospital of Wales, Cardiff, United Kingdom.ORCID http://orcid.org/0000-0002-2612-4621
Lars HjorthPediatrics, Department of Clinical Sciences Lund, Skane University Hospital, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-8302-7174
Katja BaustDepartment of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0002-4980-1138
Mark BernsteinIWK Health Centre, Dalhousie University, Halifax, NS, Canada.ORCID http://orcid.org/0000-0003-2019-8627
Stefan BielackCooperative Osteosarcoma Study Group, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.ORCID http://orcid.org/0000-0003-2144-3153
Patricia De VosDepartment of Pediatric Hematology and Oncology, Gent University Hospital, Gent, Belgium.ORCID http://orcid.org/0000-0002-5786-0015
Pancras C W HogendoornDepartment of Pathology, Leiden University Medical Center, Leiden, Netherlands.ORCID http://orcid.org/0000-0002-1513-8104
Gordana JovicMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.ORCID http://orcid.org/0000-0002-2109-4945
Mark KrailoDepartment of Preventive Medicine, Keck Medical Center at the University of Southern California, Los Angeles, CA, United States.ORCID http://orcid.org/0000-0002-7608-0698
Kiana KreitzInstitute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.ORCID http://orcid.org/0000-0003-3691-1773
Neyssa MarinaFive Prime Therapeutics Inc, South San Francisco, CA, United States.ORCID http://orcid.org/0000-0002-7195-8887
Babasola O PopoolaMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.ORCID http://orcid.org/0000-0001-6869-3315
Cristina SauerlandInstitute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.ORCID http://orcid.org/0000-0002-8748-8218
Sigbjørn SmelandDivision of Cancer Medicine and Scandinavian Sarcoma Group, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-5743-8244
Carmen TeskeDepartment of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0001-8736-0292
Clara V SchweinitzDepartment of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0003-4259-5770
Jeremy WhelanDepartment of Oncology, University College Hospital, London, United Kingdom.ORCID http://orcid.org/0000-0001-6793-5722
Andreas WienerWest German Proton Therapy Centre Essen, Essen, Germany.ORCID http://orcid.org/0000-0001-5835-4264
Matthew R SydesMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.ORCID http://orcid.org/0000-0002-9323-1371
Rajaram NagarajanDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.ORCID http://orcid.org/0000-0003-1933-6180
University Hospital Bonn · DEMRC Clinical Trials Unit at UCL · GBCincinnati Children's Hospital Medical Center · USDalhousie University · CAFive Prime Therapeutics (United States) · USGhent University Hospital · BELeiden University Medical Center · NLLund University · SEOlgahospital · DEOslo University Hospital · NOUniversity College Hospital · GBUniversity Hospital of Wales · GBUniversity of Southern California · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Medical Research Council MC_EX_UU_G0400248Medical Research Council MC_UU_12023/28NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

backgroundThe quality of life (QoL) of patients with osteosarcoma (OS) may be adversely affected by the disease or its treatment. Therefore, it is important to understand the QoL of patients undergoing treatment for OS to improve the QoL. We report on the first prospective international QoL study that was embedded within a large randomized clinical trial from 4 national study groups.

objectiveThis paper aimed to describe the QoL study development, methodology, accrual details, and characteristics of the QoL cohort.

methodsA total of 2260 patients registered in the EURopean AMerican Osteosarcoma Study-1 (EURAMOS-1), of whom 97.92% (2213/2260) were eligible for the optional QoL assessment and could participate in terms of questionnaire availability. Overall, 61.86% (1369/2213) of patients and/or proxies completed the QoL evaluation at the first assessment time point (E1) after the start of preoperative treatment. The QoL measures used (self- and/or proxy reports) depending on the patient's age and national study group. Participants and nonparticipants in the ancillary QoL study were compared regarding relevant demographic and disease-related characteristics at registration in the trial.

resultsThe participation rate at time point E1 did not differ with regard to age, gender, the occurrence of pathological fracture, or the presence of any metastases at diagnosis. No differences were found regarding the primary tumor site. Only the national study group affiliation had an influence on participation. Participation decreased linearly with trial progress up to 20% at the final time point of QoL assessment.

conclusionsThis study demonstrates the feasibility of international cooperation for the purpose of assessing and understanding the QoL of pediatric and adolescent/young adult patients with cancer. Future outcomes of this QoL substudy will help to adapt interventions to improve QoL.

Indexed as

adolescentcancerchildobservational studyosteosarcomaquality of lifesarcomasurvivors of childhood canceryoung adult

Identifiers

PMID31573951
PMCPMC6819132
OpenAlexW2975109673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.